The Thyroid Genetic Classifier to safely forgo unnecessary diagnostic thyroid surgery for indeterminate cytology

Approximately 20% of indeterminate nodules (Bethesda III/IV) are managed through diagnostic surgery, which is the standard approach. After surgery, up to 75% of these nodules are determined to be benign. ThyroidPrint reclassifies nodules as either benign or suspicious of malignancy, aiding decision-making, avoiding patients to undergo unnecessary surgeries, and reducing healthcare costs.

ThyroidPrint® clinical pathway in case of thyroid nodule detection

ThyroidPrint® accurately classifies indeterminate thyroid nodules with 95% NPV

ThyroidPrint® Clinical Utility Study reduces unnecessary surgery by 67%
**Idylla™ ThyroidPrint® Assay**

The **first-in-class assay** in kit format for indeterminate thyroid nodules

For Research Use Only, assay currently under development

---

**Idylla™ ThyroidPrint® Assay**

- **qPCR of 10 genes in a diagnostic kit**
  - Tumor Inflammatory microenvironment Genes: CXCR3, CXCL10, CXCL9, CXCL7, CXCL8
  - Tumor Epithelial Genes: TIMP1, CLDN1, KRT19
  - Stabilizing Genes: AFAP1L2, HMOX1

- **Proprietary algorithm analysis**

---

**Unique sample-to-insight seamless workflow**

1. **Scan Sample & Cartridge**
2. **Insert Sample in the Cartridge**
3. **Insert Cartridge in the Idylla™ Platform and obtain the result within 3 hours**

---

(1) Haugen et al., 2015 American Thyroid Association Management guidelines for adult patients. Thyroid, 2016
(2) Gonzalez et al., A 10-Gene Classifier for Indeterminate Thyroid Nodules: Development and Multicenter Accuracy Study. Thyroid, 2017
(3) Zafereo et al., A Thyroid Genetic Classifier Correctly Predicts Benign Nodules with Indeterminate Cytology: Two Independent, Multicenter, Prospective Validation Trials. Thyroid, 2020
(4) Olmos et al., ThyroidPrint®: clinical utility for indeterminate thyroid cytology. End Rel Cancer, 2023

---

thyroidprint.com/wctc

---

*ThyroidPrint® LDT currently available as a Laboratory Developed Test in GeneproDx' CAP accredited laboratory in Santiago de Chile (Chile).

**Idylla™ ThyroidPrint®** is currently under development and planned to be released as an assay for Research Use Only, not for use in diagnostic procedures.

© Biocartis NV, June 2023. All rights reserved.